Efficacy of Osimertinib in Patients With Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Advanced Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
- Status
- RECRUITING
- Phase
- PHASE3
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
- Status
- RECRUITING
- Phase
- PHASE1
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3